Physician profile
Angela Scott
NPI 1679502934
$2,362.56
in general payments reported to CMS, 2019-2025
24 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $128 · 2021: $163 · 2022: $224 · 2023: $156 · 2024: $1,290 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856 · Travel and Lodging: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.99 |
| Travel and Lodging | $766.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $1,028.90 | 2024 | |
| Amgen INC. | $180.02 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $144.72 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Abbvie INC. | $141.38 | 2022-2024 | Vuity, Alphagan P, Lumigan |
| Allergan, INC. | $106.92 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $104.88 | 2020-2025 | |
| Carl Zeiss Meditec, INC. | $79.40 | 2019 | |
| Kala Pharmaceuticals, INC. | $69.10 | 2021-2022 | |
| Horizon Therapeutics Plc | $50.90 | 2023 | Tepezza |
| Alcon Vision LLC | $49.06 | 2019-2023 | Simbrinza |
| Harrow Eye, LLC | $45.77 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $44.31 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $41.55 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.61 | 2019-2020 | |
| Sight Sciences, INC. | $33.81 | 2019-2024 | Omni Surgical System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $30.64 | 2019 | |
| Springworks Therapeutics, INC. | $29.81 | 2024 | Ogsiveo |
| Dompe US, INC. | $28.47 | 2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $28.41 | 2020-2021 | |
| Omeros Corporation | $22.04 | 2019 | |
| Glaukos Corporation | $21.73 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $16.47 | 2024 | Xdemvy |
| Rxsight INC | $15.17 | 2023 | Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
| Mallinckrodt Hospital Products INC. | $14.49 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.